Adjusted comparison of teclistamab versus real-world physician's choice (RWPC) of therapy in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) Meeting Abstract


Authors: Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; Ammann, E.; Chastain, K.; Parekh, T.; Marshall, A.; Slavcev, M.; Moreau, P.
Abstract Title: Adjusted comparison of teclistamab versus real-world physician's choice (RWPC) of therapy in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Meeting Title: ISPOR Europe 2023
Journal Title: Value in Health
Volume: 26
Issue: 12 Suppl.
Meeting Dates: 2023 Nov 12-15
Meeting Location: Copenhagen, Denmark
ISSN: 1098-3015
Publisher: Elsevier Science, Inc.  
Date Published: 2023-12-01
Start Page: S5
Language: English
ACCESSION: WOS:001137279500018
PROVIDER: wos
DOI: 10.1016/j.jval.2023.09.026
Notes: Meeting Abstract: P18 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Saad Zafar Usmani
    297 Usmani